PEAK6 Investments L.P. cut its position in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 18.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 55,000 shares of the medical device company’s stock after selling 12,652 shares during the quarter. PEAK6 Investments L.P.’s holdings in NxStage Medical were worth $1,333,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of NxStage Medical during the 4th quarter valued at $896,000. Guggenheim Capital LLC grew its holdings in shares of NxStage Medical by 35.5% in the 4th quarter. Guggenheim Capital LLC now owns 11,247 shares of the medical device company’s stock worth $273,000 after acquiring an additional 2,949 shares during the last quarter. EnTrustPermal Partners Offshore LP acquired a new position in shares of NxStage Medical in the 4th quarter worth $6,457,000. Wolverine Asset Management LLC grew its holdings in shares of NxStage Medical by 210.7% in the 4th quarter. Wolverine Asset Management LLC now owns 115,580 shares of the medical device company’s stock worth $2,800,000 after acquiring an additional 78,380 shares during the last quarter. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of NxStage Medical in the 4th quarter worth $975,000. Institutional investors own 84.26% of the company’s stock.
A number of brokerages recently issued reports on NXTM. Zacks Investment Research cut NxStage Medical from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. BidaskClub upgraded NxStage Medical from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Finally, ValuEngine cut NxStage Medical from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Three research analysts have rated the stock with a sell rating and eight have issued a hold rating to the stock. The company has an average rating of “Hold” and a consensus price target of $30.25.
In other news, SVP Winifred L. Swan sold 3,500 shares of the firm’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $25.35, for a total value of $88,725.00. Following the completion of the sale, the senior vice president now owns 14,270 shares of the company’s stock, valued at $361,744.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 10,500 shares of company stock valued at $261,485. 4.70% of the stock is currently owned by insiders.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.